Storia in 5 fonti

FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

The FDA has expanded approval for a radioligand therapy that nearly doubles the number of men with advanced prostate cancer eligible to receive the treatment, according to a Novartis press release.Men with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer can now use lutetium Lu-177 vipivotide tetraxetan (Pluvicto, Novartis) in combination with an

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 g fa

FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

originale

FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

Confronto fonti

FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

Timeline cronologica

FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)

Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31

Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)

Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31